$AZN  Selumetinib, co-developed and co-commercialised with MSD Inc., has been granted orphan drug designation (ODD) in Japan for the treatment of #neurofibromatosis type 1 (#NF1), a rare and debilitating genetic disease.

#AstraZeneca $MRK #pharma #singlestockETPs